Confo Therapeutics

A big thank you to Brad Loncar and BiotechTV for visiting our Ghent headquarters for an engaging interview with our CEO, Cedric Ververken! It was a pleasure to share the Confo story and how our unique expertise in GPCRs is driving innovation in drug discovery and development.   From diving into the science behind our innovative platform to highlighting our programs in pain and obesity as well as our strategic partnerships, Cedric enjoyed the opportunity to discuss our vision and progress.   Watch the full interview below to learn more about what sets Confo apart.

Team Confo’s Unforgettable Off-Site Adventure! We just wrapped up an amazing team-building retreat with our entire team at the relaxing Belgian coast. It was a fantastic chance to step away from our daily routines, connect on a personal level, and celebrate our team’s many achievements. It was the perfect mix of work, play, and team connection. We have returned inspired, motivated, and ready to tackle new challenges together. A massive thanks to our amazing team, who made this trip so special and fun. Here’s to more Confo adventures and collaborations!   #TeamBuilding #CompanyCulture #ConfoAdventures

Thrilled to share that our team has published groundbreaking research in 𝘕𝘢𝘵𝘶𝘳𝘦 𝘊𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯𝘴. We revealed the world’s first structure of a complex between an antibody-based agonist and a Class A GPCR - specifically the melanocortin receptor 4 (MC4R), a critical regulator of hunger and satiety. This was achieved using our proprietary technology platform. Our findings lay the foundation for further exploration of MCR4 agonists as treatments of obesity, with the potential to open novel therapeutic avenues.   Read more about the announcement here: https://lnkd.in/ekdT8zpu

Today we are thrilled to announce the close of our €60 million Series B financing round led by Ackermans & van Haaren. We also welcome our other new investors, Driehaus Capital Management LLC and Quest for Growth, as they participate with our existing investors in this funding round.   The funds will advance our metabolic and rare endocrine disease programs including 2 through Phase 1, and 2 to IND approval. We thank our international investors for their support and look forward to accelerating our ambitious development pipeline.   Read more about the announcement here: https://lnkd.in/eha9QXFz

Today Confo announced that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant will be used to expand Confo’s ongoing R&D efforts using its patent-protected technology platform for the discovery of next-generation medicines targeting Class B GPCRs for the treatment of a range of endocrine and metabolic diseases including obesity. Access the full press release at: https://lnkd.in/eSyCJRps